- Zymeworks to buy Theravance Biopharma for $17.00/share plus CVR tied to ampreloxetine (80% net proceeds to TBPH), $50M milestone, 10% net sales share; closing H2 2026, subject to approvals.
- Theravance Biopharma (TBPH) expects a deal to close in H2 after accelerating a strategic review and restructuring, including major layoffs following the Phase 3 ampreloxetine failure
TradingView
Key facts: Zymeworks to buy Theravance for $17/share; CVR, layoffs
Zymeworks to buy Theravance Biopharma for $17.00/share plus CVR tied to ampreloxetine (80% net proceeds to TBPH), $50M milestone, 10% net sales share; closing H2 2026, subject to a